Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-06-16

DEVELOPMENT OF NEW GYRASE INHIBITORS BY COMBINATORIAL BIOSYNTHESIS

Obiettivo

The aim of this project is to generate novel inhibitors of gyrase and topoisomerase IV by engineering the biosynthetic pathways of very potent natural inhibitors of these enzymes. The project will focus on antibiotics of the aminocoumarin type (novobiocin, clorobiocin, coumermycin A1, simocyclinones) and the cyclothialidine type (cyclothialidine and GR12222X). All these compounds are produced by Stneptomyces strains. The interaction of novobiocin, clorobiocin and the cyclothialidines with bacterial gyrase has been elucidated with biophysical and X-ray crystallographic techniques by members of this consortium. The interaction of the simocyclinones, and of newly generated inhibitors, with gyrase and topoisomerase IV will be investigated in this project. The results will be utilized for rational approaches for the development of new inhibitors by genetic engineering. The complete gene clusters involved in the biosynthesis of novobiocin, clorobiocin, coumermycin and simocyclinone have been cloned and sequenced by the members of this consortium. The biosynthetic gene cluster of cyclothialidine will be identified in this project. Genes and operons within the gene clusters will be modified by gene inactivation, gene expression or gene replacement experiments within the natural producers. Furthermore, vectors containing entire biosynthetic gene clusters will be modified in E. coli and subsequently introduced into suitable Streptomyces host strains for production of novel metabolites. New molecules will also be generated by feeding specific strains with synthetic analogues of precursors of biosynthesis. Accumulated compounds will be modified chemically in order to generate an even wider array of new molecules. The biological activity of the novel molecules will be assayed using enzyme assay systems with gyrase and topoisomerase IV and antibacterial assays with human pathogens. Promising drug candidates will be investigated in animal infection models...

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

FP6-2002-LIFESCIHEALTH
Vedi altri progetti per questo bando

Meccanismo di finanziamento

STREP - Specific Targeted Research Project

Coordinatore

EBERHARD KARLS-UNIVERSITAET TUEBINGEN
Contributo UE
Nessun dato
Indirizzo
Wilhelmstrasse 7
TUEBINGEN
Germania
Costo totale
Nessun dato

Partecipanti (6)